CAR-T was developed to wipe out hard-to-treat blood cancers. But the cells that go bad in leukemias and lymphomas — immune ...
For industry-sponsored trials in autoimmune inflammation therapeutic areas, the dominating indications include atopic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback